Start free trial

Latest Definium Therapeutics News & Updates

See the latest news and media coverage for Definium Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Definium Therapeutics

Psychedelic medicine company for brain health disorders

definiumtx.com
Headquarters
New York, United States
Founded year
2019
Company type
Public company
Number of employees
170–200
Industry
Pharmaceuticals

Last updated

Latest news about Definium Therapeutics

In short: Definium Therapeutics reported three positive DT120 Phase 3 readouts and planned Q4 pre-NDA meetings

Company announcements

Definium Therapeutics

Definium Therapeutics reports second-quarter results and clinical progress

The company reported $1.1 billion in cash, positive Phase 3 MDD results, completed enrollment in two GAD trials, and raised $805 million through a public offering.

Unlock all announcements with a

Media coverage

The Globe and Mail

Definium reports positive Phase 3 results for DT120

An update from Definium Therapeutics ( (DFTX)) is now available. On September 14, 2026, Definium Therapeutics reported positive topline results from Panorama, its second Phase...

The Globe and Mail

Definium Therapeutics Gains FDA Breakthrough for Depression Drug

Detailed price information for Definium Therapeutics Inc (DFTX-Q) from The Globe and Mail including charting and trades.

Unlock all articles with a

Never miss news about Definium Therapeutics

Track Definium Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Definium Therapeutics competitors & trending companies

Browse news for competitors to Definium Therapeutics and other trending companies.